Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Systematic review of clinical risk markers

Europace

Volumn 12, Issue 3, 2010, Pages 313-321

  Christiaans, Imke ^a   Van Engelen, Klaartje ^a   Van Langen, Irene M ^a   Birnie, Erwin ^b   Bonsel, Gouke J ^b   Elliott, Perry M ^c   Wilde, Arthur A M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiomyopathy; Hypertrophic cardiomyopathy; Prognosis; Risk factors; Sudden death

Indexed keywords

BLOOD PRESSURE; DISEASE MARKER; FAMILY HISTORY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; SURVIVAL; SYNCOPE; SYSTEMATIC REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77749324910     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup431     Document Type: Review

References (65)

1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2008;29:270-6.
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 2006;113:1807-16.
3. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:697-704.
4. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92:785-91.
5. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
6. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines. J Am Coll Cardiol 2003;42:1687-713.
7. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992;86:730-40.
8. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989;13:1283-8.
9. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hyper-trophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596- 601.
10. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41:987-93.
11. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743-7.
12. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
13. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-4.
14. Dimitrow PP, Dubiel JS. Echocardiographic risk factors predisposing to sudden cardiac death in hypertrophic cardiomyopathy. Heart 2005;91:93-4.
15. Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005;46:1543-50.
16. Doi Y, Kitaoka H. Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation. J Cardiol 2001;37:133-8.
17. Kofflard MJ, Waldstein DJ, Vos J, Ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993;72:939-43.
18. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33: 2044-51.
19. Pelliccia F, Cianfrocca C, Cristofani R, Romeo F, Reale A. Electrocardiographic findings in patients with hypertrophic cardiomyopathy. Relation to presenting features and prognosis. J Electrocardiol 1990;23:213-22.
20. Romeo F, Pelliccia F, Cristofani R, Martuscelli E, Reale A. Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant? Eur Heart J 1990;11:233-40.
21. D'Andrea A, Caso P, Cuomo S, Salerno G, Scarafile R, Mita C et al. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes. Br J Sports Med 2006;40:244-50.
22. D'Andrea A, Caso P, Severino S, Cuomo S, Capozzi G, Calabro P et al. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1311-8.
23. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-41.
24. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42: 873-9.
25. Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774-8.
26. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206-11.
27. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005;45:1076-80.
28. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
29. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
30. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
31. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:315-21.
32. Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990;16:821-6.
33. Bongioanni S, Bianchi F, Migliardi A, Gnavi R, Pron PG, Casetta M et al. Relation of QRS duration to mortality in a community-based cohort with hypertrophic cardiomyopathy. Am J Cardiol 2007;100:503-6.
34. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24.
35. Cannan CR, Reeder GS, Bailey KR, Melton LJI, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995;92:2488-95.
36. Higashikawa M, Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J 1997;61:673-81.
37. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003;108:2342-8.
38. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
39. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS et al. Genderrelated differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:480-7.
40. Marian AJ, Mares A Jr, Kelly DP, Yu QT, Abchee AB, Hill R et al. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. Eur Heart J 1995;16:368-76.
41. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280-5.
42. Hwang TH, Lee WH, Kimura A, Satoh M, Nakamura T, Kim MK et al. Early expression of a malignant phenotype of familial hypertrophic cardiomyopathy associated with a Gly716Arg myosin heavy chain mutation in a Korean family. Am J Cardiol 1998;82:1509-13.
43. Marian AJ, Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998;9: 88-99.
44. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
45. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part II. Circulation 2001;104:2249-52.
46. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994;89:22-32.
47. Consevage MW, Salada GC, Baylen BG, Ladda RL, Rogan PK. A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. Hum Mol Genet 1994;3:1025-6.
48. Coviello DA, Maron BJ, Spirito P, Watkins H, Vosberg HP, Thierfelder L et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a 'hot spot' in the alpha-tropomyosin gene. J Am Coll Cardiol 1997;29:635-40.
49. Havndrup O, Bundgaard H, Andersen PS, Larsen LA, Vuust J, Kjeldsen K et al. The Val606Met mutation in the cardiac beta-myosin heavy chain gene in patients with familial hypertrophic cardiomyopathy is associated with a high risk of sudden death at young age. Am J Cardiol 2001;87:1315-7.
50. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation 1992;86:345-52.
51. Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA et al. Prevalence and severity of 'benign' mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 2002;106:3085-90.
52. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998;97: 2230-6.
53. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Bonne G et al. Genotypephenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J 1998;19:139-45.
54. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-57.
55. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-32.
56. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:1903-10.
57. Erdmann J, Raible J, Maki-Abadi J, Hummel M, Hammann J, Wollnik B et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001;38: 322-30.
58. Revera M, Van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA et al. Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression. Cardiovasc J Afr 2007;18:146-53.
59. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation 2000;102:1950-5.
60. Lekanne Deprez RH, Muurling-Vlietman JJ, Hruda J, Baars MJ, Wijnaendts LC, Stolte-Dijkstra I et al. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene. J Med Genet 2006;43:829-32.
61. Richard P, Isnard R, Carrier L, Dubourg O, Donatien Y, Mathieu B et al. Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet 1999;36:542-5.
62. Richard P, Charron P, Leclercq C, Ledeuil C, Carrier L, Dubourg O et al. Homozygotes for a R869G mutation in the beta-myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:1575-83.
63. Cuoco FA, Spencer WH III, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;52:1718-23.
64. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12.
65. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007;28:2583-8.